Latest news with #PeteAnevski
Yahoo
19-05-2025
- Business
- Yahoo
Q1 Earnings Outperformers: Progyny (NASDAQ:PGNY) And The Rest Of The Health Insurance Providers Stocks
Looking back on health insurance providers stocks' Q1 earnings, we examine this quarter's best and worst performers, including Progyny (NASDAQ:PGNY) and its peers. Upfront premiums collected by health insurers lead to reliable revenue, but profitability ultimately depends on accurate risk assessments and the ability to control medical costs. Health insurers are also highly sensitive to regulatory changes and economic conditions such as unemployment. Going forward, the industry faces tailwinds from an aging population, increasing demand for personalized healthcare services, and advancements in data analytics to improve cost management. However, continued regulatory scrutiny on pricing practices, the potential for government-led reforms such as expanded public healthcare options, and inflation in medical costs could add volatility to margins. One big debate among investors is the long-term impact of AI and whether it will help underwriting, fraud detection, and claims processing or whether it may wade into ethical grey areas like reinforcing biases and widening disparities in medical care. The 11 health insurance providers stocks we track reported a strong Q1. As a group, revenues beat analysts' consensus estimates by 3% while next quarter's revenue guidance was in line. Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 8.4% since the latest earnings results. Pioneering a data-driven approach to family building that has achieved an industry-leading patient satisfaction score of +80, Progyny (NASDAQ:PGNY) provides comprehensive fertility and family building benefits solutions to employers, helping employees access quality fertility treatments and support services. Progyny reported revenues of $324 million, up 16.5% year on year. This print exceeded analysts' expectations by 5%. Overall, it was a satisfactory quarter for the company with an impressive beat of analysts' sales volume estimates. 'We're pleased with the strong start to the year, highlighted by both our solid financial results as well as the progress made with our investments to expand the platform and extend our leading position as the solution of choice in women's health and family building,' said Pete Anevski, Chief Executive Officer of Progyny. Progyny delivered the weakest full-year guidance update of the whole group. Unsurprisingly, the stock is down 10% since reporting and currently trades at $21.03. Is now the time to buy Progyny? Access our full analysis of the earnings results here, it's free. With over 9,000 retail pharmacy locations serving as neighborhood health destinations across America, CVS Health (NYSE:CVS) operates retail pharmacies, provides pharmacy benefit management services, and offers health insurance through its Aetna subsidiary. CVS Health reported revenues of $94.59 billion, up 7% year on year, outperforming analysts' expectations by 1.5%. The business had an exceptional quarter with an impressive beat of analysts' same-store sales estimates and a solid beat of analysts' EPS estimates. Although it had a fine quarter compared to its peers, the market seems unhappy with the results as the stock is down 6.5% since reporting. It currently trades at $62.36. Is now the time to buy CVS Health? Access our full analysis of the earnings results here, it's free. With over 100 million people served across its various businesses and a workforce of more than 400,000, UnitedHealth Group (NYSE:UNH) operates a health insurance business and Optum, a healthcare services division that provides everything from pharmacy benefits to primary care. UnitedHealth reported revenues of $109.6 billion, up 9.8% year on year, falling short of analysts' expectations by 1.7%. It was a softer quarter as it posted a significant miss of analysts' full-year EPS guidance estimates and a slight miss of analysts' EPS estimates. UnitedHealth delivered the weakest performance against analyst estimates in the group. The company added 395,000 customers to reach a total of 54.12 million. As expected, the stock is down 50.9% since the results and currently trades at $287.66. Read our full analysis of UnitedHealth's results here. Founded in 2013 with a mission to transform healthcare for seniors, Alignment Healthcare (NASDAQ:ALHC) provides Medicare Advantage health plans for seniors with features like concierge services, transportation benefits, and technology-driven care coordination. Alignment Healthcare reported revenues of $926.9 million, up 47.5% year on year. This number beat analysts' expectations by 4.4%. Overall, it was a very strong quarter as it also put up a solid beat of analysts' EPS estimates. Alignment Healthcare achieved the fastest revenue growth among its peers. The company added 28,400 customers to reach a total of 217,500. The stock is down 10.2% since reporting and currently trades at $15.00. Read our full, actionable report on Alignment Healthcare here, it's free. With roots dating back to 1792 and serving millions of customers across the globe, The Cigna Group (NYSE:CI) provides healthcare services through its Evernorth Health Services and Cigna Healthcare segments, offering pharmacy benefits, specialty care, and medical plans. Cigna reported revenues of $65.5 billion, up 14.4% year on year. This result surpassed analysts' expectations by 8.4%. More broadly, it was a satisfactory quarter as it also recorded a decent beat of analysts' EPS estimates but a significant miss of analysts' customer base estimates. Cigna scored the biggest analyst estimates beat among its peers. The company lost 1.14 million customers and ended up with a total of 16.36 million. The stock is down 5.3% since reporting and currently trades at $317. Read our full, actionable report on Cigna here, it's free. Thanks to the Fed's rate hikes in 2022 and 2023, inflation has been on a steady path downward, easing back toward that 2% sweet spot. Fortunately (miraculously to some), all this tightening didn't send the economy tumbling into a recession, so here we are, cautiously celebrating a soft landing. The cherry on top? Recent rate cuts (half a point in September 2024, a quarter in November) have propped up markets, especially after Trump's November win lit a fire under major indices and sent them to all-time highs. However, there's still plenty to ponder — tariffs, corporate tax cuts, and what 2025 might hold for the economy. Want to invest in winners with rock-solid fundamentals? Check out our 9 Best Market-Beating Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. Join Paid Stock Investor Research Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-05-2025
- Business
- Yahoo
Progyny, Inc. to Present at BofA Securities 2025 Health Care Conference
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that Progyny's Chief Executive Officer, Pete Anevski, and Chief Financial Officer, Mark Livingston, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025, at 3:00 P.M. Pacific Time / 6:00 P.M. Eastern Time. A live audiocast and replay will be available from the Events and Presentations section of Progyny's website at About Progyny Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients and physicians. Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit For Further Information, Please Contact:Investors:James Hartinvestors@ Media:Alexis Fordmedia@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-05-2025
- Business
- Yahoo
Progyny, Inc. to Present at BofA Securities 2025 Health Care Conference
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that Progyny's Chief Executive Officer, Pete Anevski, and Chief Financial Officer, Mark Livingston, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025, at 3:00 P.M. Pacific Time / 6:00 P.M. Eastern Time. A live audiocast and replay will be available from the Events and Presentations section of Progyny's website at About Progyny Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients and physicians. Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit For Further Information, Please Contact:Investors:James Hartinvestors@ Media:Alexis Fordmedia@
Yahoo
09-05-2025
- Business
- Yahoo
PGNY Q1 Earnings Call: Product Expansion, Member Growth, and Guidance Raised
Fertility benefits company Progyny (NASDAQ:PGNY) reported Q1 CY2025 results exceeding the market's revenue expectations , with sales up 16.5% year on year to $324 million. The company expects next quarter's revenue to be around $317.5 million, close to analysts' estimates. Its non-GAAP profit of $0.48 per share was 7.7% above analysts' consensus estimates. Is now the time to buy PGNY? Find out in our full research report (it's free). Revenue: $324 million vs analyst estimates of $308.7 million (16.5% year-on-year growth, 5% beat) Adjusted EPS: $0.48 vs analyst estimates of $0.45 (7.7% beat) Adjusted EBITDA: $57.79 million vs analyst estimates of $54.71 million (17.8% margin, 5.6% beat) The company slightly lifted its revenue guidance for the full year to $1.21 billion at the midpoint from $1.2 billion Management raised its full-year Adjusted EPS guidance to $1.59 at the midpoint, a 1.3% increase EBITDA guidance for the full year is $196.5 million at the midpoint, in line with analyst expectations Operating Margin: 7.5%, in line with the same quarter last year Free Cash Flow Margin: 14.5%, up from 8.9% in the same quarter last year Sales Volumes rose 9.2% year on year (12.4% in the same quarter last year) Market Capitalization: $2 billion Progyny's first quarter results reflected increased client adoption and higher member engagement, with management attributing revenue growth to a rise in covered lives and continued demand for its fertility and women's health solutions. CEO Pete Anevski pointed to shifting demographic trends, such as later family planning among women, as key factors driving the need for Progyny's services. He also noted, "Employers can proactively manage these risks through Progyny's comprehensive solution," referencing the company's role in addressing high-risk pregnancies and related costs for employers. Looking ahead, management raised both revenue and adjusted earnings guidance for the year, citing a healthy sales pipeline and early positive feedback on new service modules. CFO Mark Livingston cautioned that future margins could moderate due to ongoing investments but expects full-year gross margin expansion versus last year. The company continues to monitor macroeconomic headwinds and client decision timelines, but Anevski said, "We entered this season feeling well positioned," emphasizing stable demand across diverse industries. Progyny's management identified several factors shaping Q1 results and the outlook for the year, including shifts in member demographics, product portfolio expansion, and sales pipeline activity. Member Demographic Shifts: Management highlighted ongoing societal trends of women postponing childbirth into their 30s and 40s, which increases the prevalence of infertility and drives demand for fertility benefits. New Product Modules: Recent launches in maternity, postpartum, and menopause support are seeing strong market interest, especially the menopause product due to its broader addressable audience. Management expects these modules to deepen client relationships over time. Sales Pipeline Activity: The current pipeline is comparable in dollar value to last year, but average covered lives per opportunity are slightly lower, which management attributes to timing and macroeconomic factors. However, there is no apparent slowdown in employer decision-making or RFP activity. Client Retention and Upsell: Approximately 20–25% of existing clients typically expand their suite of services annually, with last year's growth in upsells reaching 30%, boosted by new women's health solutions. Transition of Large Client: Revenue this quarter included contributions from a large former client under a transition of care agreement, but even excluding this, core business growth remained robust. Management emphasized that member base expansion continues despite client churn. Management expects future performance to be shaped by a combination of sustained employer demand for women's health benefits, ongoing portfolio investments, and macroeconomic conditions. Portfolio Investments Continue: Ongoing investments in platform and product capabilities, including integration of recent acquisitions, are expected to support long-term growth but may temper short-term profit margins. Stable Demand Environment: Management sees consistent demand from employers seeking to address shifting workforce demographics and retain talent, though some uncertainty remains due to broader economic factors. Sales and Upsell Strategy: The company's focus on expanding relationships with existing clients through upsells and cross-selling of new modules is expected to contribute meaningfully to revenue growth in future periods. Anne Samuel (JPMorgan): Asked about muted seasonality in cycles per utilizer for Q2; management cited guidance caution due to uncertainty, not a change in underlying trends. Jailendra Singh (Truist Securities): Questioned potential delays in employer RFPs for 2026 launches; management said there was no slowdown in decision-making or sales cycles. Michael Cherny (Leerink Partners): Inquired about which new women's health modules are seeing the most engagement; management pointed to higher initial uptake for the menopause product due to its broad applicability. David Michael (BTIG): Sought clarity on the impact of potential tariffs on specialty medications; management indicated minimal current impact and flexibility to mitigate any future cost increases. Sarah James (Cantor Fitzgerald): Asked for more detail on gross margin expansion and investment spending; management confirmed ongoing investments in platform and product capabilities totaling about $15 million for the year. In the coming quarters, the StockStory team will monitor (1) the progress and adoption rates of Progyny's new service modules, particularly in maternity and menopause support; (2) the pace and scale of new client acquisitions and upsell activity within the existing client base; and (3) the company's ability to manage investments while maintaining or expanding margins. We will also watch for any macroeconomic shifts or regulatory changes that could influence employer benefit decisions. Progyny currently trades at a forward P/E ratio of 14.2×. Should you load up, cash out, or stay put? The answer lies in our free research report. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today. Sign in to access your portfolio
Yahoo
08-05-2025
- Business
- Yahoo
Progyny (NASDAQ:PGNY) Posts Better-Than-Expected Sales In Q1, Provides Optimistic Revenue Guidance for Next Quarter
Fertility benefits company Progyny (NASDAQ:PGNY) beat Wall Street's revenue expectations in Q1 CY2025, with sales up 16.5% year on year to $324 million. On top of that, next quarter's revenue guidance ($317.5 million at the midpoint) was surprisingly good and 3.1% above what analysts were expecting. Its non-GAAP profit of $0.48 per share was 7.7% above analysts' consensus estimates. Is now the time to buy Progyny? Find out in our full research report. Revenue: $324 million vs analyst estimates of $308.7 million (16.5% year-on-year growth, 5% beat) Adjusted EPS: $0.48 vs analyst estimates of $0.45 (7.7% beat) Adjusted EBITDA: $57.79 million vs analyst estimates of $54.71 million (17.8% margin, 5.6% beat) The company slightly lifted its revenue guidance for the full year to $1.21 billion at the midpoint from $1.2 billion Management raised its full-year Adjusted EPS guidance to $1.59 at the midpoint, a 1.3% increase EBITDA guidance for the full year is $196.5 million at the midpoint, in line with analyst expectations Operating Margin: 7.5%, in line with the same quarter last year Free Cash Flow Margin: 14.5%, up from 8.9% in the same quarter last year Sales Volumes fell 99.9% year on year (12.4% in the same quarter last year) Market Capitalization: $2.01 billion 'We're pleased with the strong start to the year, highlighted by both our solid financial results as well as the progress made with our investments to expand the platform and extend our leading position as the solution of choice in women's health and family building,' said Pete Anevski, Chief Executive Officer of Progyny. Pioneering a data-driven approach to family building that has achieved an industry-leading patient satisfaction score of +80, Progyny (NASDAQ:PGNY) provides comprehensive fertility and family building benefits solutions to employers, helping employees access quality fertility treatments and support services. Reviewing a company's long-term sales performance reveals insights into its quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Thankfully, Progyny's 35.7% annualized revenue growth over the last five years was incredible. Its growth beat the average healthcare company and shows its offerings resonate with customers. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Progyny's annualized revenue growth of 17.9% over the last two years is below its five-year trend, but we still think the results suggest healthy demand. Progyny also reports its number of units sold, which reached 16,160 in the latest quarter. Over the last two years, Progyny's units sold averaged 2.9% year-on-year growth. Because this number is lower than its revenue growth, we can see the company benefited from price increases. This quarter, Progyny reported year-on-year revenue growth of 16.5%, and its $324 million of revenue exceeded Wall Street's estimates by 5%. Company management is currently guiding for a 4.4% year-on-year increase in sales next quarter. Looking further ahead, sell-side analysts expect revenue to grow 1.5% over the next 12 months, a deceleration versus the last two years. This projection doesn't excite us and implies its products and services will face some demand challenges. Software is eating the world and there is virtually no industry left that has been untouched by it. That drives increasing demand for tools helping software developers do their jobs, whether it be monitoring critical cloud infrastructure, integrating audio and video functionality, or ensuring smooth content streaming. Click here to access a free report on our 3 favorite stocks to play this generational megatrend. Progyny was profitable over the last five years but held back by its large cost base. Its average operating margin of 5.2% was weak for a healthcare business. On the plus side, Progyny's operating margin rose by 1.7 percentage points over the last five years, as its sales growth gave it operating leverage. The company's two-year trajectory shows its performance was mostly driven by its recent improvements. This quarter, Progyny generated an operating profit margin of 7.5%, in line with the same quarter last year. This indicates the company's overall cost structure has been relatively stable. Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Progyny's EPS grew at an astounding 106% compounded annual growth rate over the last five years, higher than its 35.7% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded. Diving into the nuances of Progyny's earnings can give us a better understanding of its performance. As we mentioned earlier, Progyny's operating margin was flat this quarter but expanded by 1.7 percentage points over the last five years. On top of that, its share count shrank by 10.4%. These are positive signs for shareholders because improving profitability and share buybacks turbocharge EPS growth relative to revenue growth. In Q1, Progyny reported EPS at $0.48, up from $0.39 in the same quarter last year. This print beat analysts' estimates by 7.7%. Over the next 12 months, Wall Street expects Progyny's full-year EPS of $1.73 to shrink by 5.2%. We enjoyed seeing Progyny beat analysts' revenue expectations this quarter. We were also glad its revenue guidance for next quarter exceeded Wall Street's estimates. On the other hand, its sales volume missed significantly and its EPS guidance for next quarter fell slightly short of Wall Street's estimates. Overall, this was a weaker quarter. The stock traded up 5% to $24.53 immediately following the results. So should you invest in Progyny right now? If you're making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
